Abstract book - ESTRO meets Asia

S74 ESTRO meets Asia 2018

recurrence, 83 patients experienced distant failure, and 59 patients died of cancer. For all patients, the 5-year LRFS, DMFS, and OS were 94.1%, 69.4 %, and 85.1 %, respectively. Pathological CR rate was 1.4 %. On multivariate analysis, nuclear grade (NG), fat infiltration and nodal ratio (NR; number of positive axillary node/removed node) were significant prognostic factors of DMFS and OS. The patients with low NG (NG1/2) had significantly better 5-year OS than patients with high NG(NG3) (89.3 % vs. 65.0 %, p = 0.001), and patients with low NR (NR<30) had significantly better 5-year OS than patients with high NR (NR ≧ 30) (93.6 % vs. 76.1 %, p=0.0003). The 5-year OS was significantly better in patients with low fat infiltration than those with high fat infiltration (95.6 % vs. 80.2 %, p=0.02). Conclusion We identified several prognostic factors in our patients; in particular, NG, NR and fat infiltration were significantly related to OS. PO-183 Bone Metastases and Prognosis in Newly Diagnosed Breast Cancer ： A Population-Based Study J. Zhang 1 , H. Gong 1 , M. Li 1 , B. Li 1 1 Shandong Cancer Hospital, Radiation oncology, Jinan, China Purpose or Objective Population-based estimates of the incidence and prognosis of bone metastases at diagnosis of breast cancer are lacking. The purpose of the current study was to characterize the incidence proportions and median survivals of patients with bone metastases in newly diagnosed breast cancer. Material and Methods Patients with breast cancer and bone metastases at the time of diagnosis from 2010 to 2014 were identified using the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute. Data were stratified by subtype, age, sex, and race. For incidence, we identified a population-based sample of adult patients diagnosed as having invasive breast cancer between 2010 and 2014 for whom the presence or absence of bone metastases at diagnosis was known. Patients diagnosed at autopsy or with an unknown follow-up were excluded from the survival analysis, leaving 302065 patients in this cohort. Survival estimates were obtained using the Kaplan-Meier method. Results We identified 10704 patients with bone metastases at the time of diagnosis of breastcancer, representing 3.54% of the entire cohort and 65.94%of the subset with metastaticdisease to any site （ 16233 patients). A total of 667 were 18 to 39 years old, 4069 were 40 to 59 years old, 4729 were 60-79 years old, and 1239 were older than 80 years. One hundred and twenty-eight were male and 10576 were female. Among the cohort with bone metastatic disease, 59.9%, 13.6%, 8.2%,5.3%, and 13.0% had HR-positive HER2-negative, HR-positive HER2- positive, triple-negative, HR-negative HER2-positive, and unknown subtypes, respectively. Median survival among patients with metastatic disease to any distant site was 28.0 months. Patients with HR-positive HER2-positive subtype displayed the longest median survival (39.0 months); patients with triple-negative subtype had the shortest median survival (9.0 months). Among the cohort with bone metastatic disease only (5185 patient), median survival was 37.0 months, and 39.0, 49.0, 13, 40.1(means for survival time), and 24.0 months, for HR-positive HER2- negative, HR-positive HER2-positive, triple-negative, HR- negative HER2-positive, and unknown subtypes, respectively. Conclusion The findings of this study provides population-based

estimates of the incidence and prognosis for patients with brain metastases at time of diagnosis of breast cancer. The findings lend support to consideration of screening imaging of the bone for patients with HR-positive or triple- negative subtypes and metastases in some other site. PO-184 Quality of Life Assessment comparison between APBI and WBI in BCS – Single Institute Experience V. Pareek 1 , R. Bhalavat 1 , M. Chandra 1 , N. Bhambhani 2 , C. Bakshi 3 , L. Nellore 1 , K. George 1 , D. Borade 1 1 Jupiter Hospital, Radiation Oncology, Mumbai, India 2 Jupiter Hospital, Surgical Oncology, Mumbai, India 3 Jupiter Hospital, Medical Oncology, Mumbai, India Introduction/ Background: With proper case selection, Accelerated Partial Breast Irradiation (APBI) with Interstitial Brachytherapy has been an effective treatment modality and has been found to be non-inferior to whole breast irradiation (WBI) in terms of local control and overall survival. In our study, we present the results of quality of life assessment comparison between APBI and WBI in early breast cancer. Methods: Among the properly selected cases for APBI, the group was retrospectively compared with patients where similar indications for APBI persisted but refused the procedure. Quality of life assessment was done with EORTC-QLQ-C30 and BR23 questionnaires. The questionnaires were assessed at baseline, immediately after completion of radiotherapy, and during 3 monthly follow up. There were 26 patients who were treated with APBI and 25 patients treated with WBI followed by tumor bed boost. Results Between January 2015 and June 2016, 51 patients were assessed. Ipsilateral local recurrence was considered as the primary end point and none of the patients achieved the same. The response to the questionnaire at the three phases of assessment was 100%. The results present the 2 year follow up evaluation of quality of life assessment in both groups. Global health status was found to be similar in both groups at baseline and at 2-year follow-up. Physical, Role and Cognitive functioning were also found to be similar. The significant difference was found to be in relation to Body image (difference of mean 12.8) and Breast Symptom function (difference of mena 13.8) in favor of APBI at 3 month follow up and non-statistical significant difference in systemic therapy side effects favoring APBI (difference of mean 8.1). Conclusion Multi catheter Interstitial APBI with proper case selection in early breast cancer after breast conserving surgery, form a non-inferior treatment option with regards to local control and survival and is logistically simpler with few factors of improved quality of life. PO-185 IMN irradiation improves disease-free survival and locoregional control in breast cancer patients X. Wang 1 1 Fudan University Shanghai Cancer Center, Radiation oncology, Shanghai, China Purpose or Objective to evaluate the effect of IMNI on DFS and locoregional control in breast cancer patients treated with postoperative RT Material and Methods Between 2007 and 2009, 873 patients in Fudan University Shanghai Cancer Center were treated with breast conserving surgery (BCS) and modified radical mastectomy (MRM) followed by postoperative RT. 784(89.8%) and 89 (10.2%) patients underwent mastectomy and breast conserving surgery, respectively. 227(26%) patients